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Model Details
The 2-strain compartmental model of TB follows the transmission of a drug susceptible strain (DS-TB) and a drug resistant strain (DR-TB), with resistance defined as a reduced probability of cure upon treatment with a novel first-line regimen. We stratify individuals into 5 separate compartments: U : Uninfected; L S :
Latently infected with DS-TB; L R : Latently infected with DR-TB; A S : Active disease with DS-TB; and A R : Active disease with DR-TB. Upon successful exposure to either TB strain (the rate of which is the product of the transmission parameter and the number of individuals with active TB resulting from the strain in question, divided by the population size, i.e., a density-dependent process), individuals progress either to active TB disease or latent TB infection. The probability of "primary progression" to active TB is given by p and includes all individuals who develop active TB within five years of infection, as estimated by Vynnycky and Fine from historical data in England and Wales [29] . The strain specific forces of infection are represented by S = A S for DS-TB and R = f A R for DR-TB, where is the transmission rate, and f is the relative transmission fitness of the DR-TB in comparison to DS-TB. Only the individuals with active TB are considered infectious.
Latently infected individuals can progress to active TB through endogenous reactivation, at a per capita rate , or by reinfection according to the process described above. Based on historical data by Sutherland et al [33] and reviewed more recently by Andrews et al [36] , individuals with latent TB infection are assumed to have a degree of partial protection against successful reinfection, 1 ⇠. Successful reinfections are assumed to have similar probability p of "primary progression" to active disease, which if such event occurs, will result in active TB with the new (superinfecting) strain. Among individuals who are successfully reinfected with the opposite strain but whose reinfection event does not result in primary progression, the probability of latent TB being drug-susceptible vs. drug resistant (ie, on endogenous reactivation) is given by the relative fitness of the two strains. Mixed-strain infections (in which individuals are simultaneously infection with both strains) are therefore not explicitly allowed.
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Individuals with active TB disease are assumed to be diagnosed and begin treatment after an average duration of 1/! for active, infectious disease, before accounting for competing rates of mortality (increased in the active TB state) and spontaneous cure. Upon diagnosis and initiation of treatment, the probability of a successful treatment is taken to be 1 k s and 1 k r for DS-TB and DR-TB, respectively. Successful treatment is modeled as a return to the latent compartment, whereas unsuccessful treatment is modeled as remaining in the infectious, active TB state. After calculating mortality rates, we maintain a stable population by matching overall birth and death rates. The following set of di↵erential equations describe the model:
E↵ective Reproductive Ratio
The algebraic expression of the e↵ective reproductive ratio, R EFF [39] is as follows:
, and A ⇤ S , are respectively, equilibrial levels of uninfected, latent TB, and active TB populations when only the drug-susceptible form of TB is circulating. In the full form, they are as follows:
S-2
The coe cient of the quadratic equation corresponding to the solution of A ⇤ S are :
When ⇠ = 0, ie, there are no reinfections, the e↵ective reproductive ratio reduces to the following form:
where, R 0,S and R 0,R are, respectively, the basic reproductive ratios for DS-TB and DR-TB.
Derivation of E↵ective Reproductive Ratio
We consider the dynamics of infections with the drug-resistant TB (DR-TB) in a population that is at equilibrium with the drug-susceptible TB (DS-TB). Let the non-negative, non-trivial, drug resistance free
. Note that the model itself does not lend to this equilibrium, because of the presence of acquisition driven resistance even in the absence any resistance in the population. We interpret this equilibrium, DRFE to exist in the absence of such acquisition, ie, with ✏ = 0. 
such that the first two are compartments where the "infected" reside. We consider the two compartments of the model, L R and A R , as the compartments carrying "infected" individuals, since we are only interested in the infections with the drug resistant strains. Let F i (x) be the rate of inflow of new infections into compartment i, and
are respectively, rates of out-and in-flows out and in to compartment i by other means (ie, flows excluding the ones considered as new infections).
and,
for i, j that belong to the "infected states", ie L R and A R .
This leads to following 2 ⇥ 2 matrices for F and V .
The inverse of V is:
The eigenvalues of F V 1 , 1,2 satisfy the characteristic equation, det(F V 1 I) = 0. In this case, the characteristic equation is:
where tr(F V 1 ), and det(F V 1 ) are, respectively, the trace and the determinant of the matrix F V 1 .
Since, the determinant of F V 1 , det(F V 1 ) = 0, the only non-zero eigenvalue is the trace of the matrix F V 1 . This is also the R EFF of DR-TB.
The drug-resistance free equilibrium can be found by solving for the model without the states L R and A R , and taking ✏ = 0.
We note that the presence of density-independent (density of A R ) acquisition of resistance, ✏, causes the e↵ective reproductive ratio, R EFF , as derived and defined above, to di↵er from the invasion criterion, R INV , such that when R INV > 1, the DR-TB is capable of invading a population at equilibrium with DS-TB and (given su cient time) replacing DS-TB as the dominant population. Specifically, while R EFF is independent of ✏, R INV is dependent on it, resulting in a scenario where for ✏ > 0, R INV > R EFF , and invasion with the resistant form is possible even when R EFF < 1. Thus, R EFF > 1 is always su cient for invasion, but is not necessary: if the acquisition rate ✏ is su ciently high to compensate for a reduction in the e↵ective reproduction, DR-TB can still supplant DS-TB at the population eventually. Table 2 : One-way model sensitivity to key model parameters. The model sensitivity to each parameter is presented as the variation in 50 year projections of % DR-TB in each of the scenarios considered, when the parameter is varied such that the resulting overall TB incidence varies from 75 to 300 per 100,000 per year. The baseline scenario is described by the parameters given in Table 1 . Scenarios I, II and III, respectively describe scenarios where acquisition rate is doubled from baseline, relative transmission is increased by 25% from the baseline, and treatment di↵erential is increased by 20% from the baseline (See Fig. 3 ). 85% treatment success describes a scenario where treatment success of DR-TB reaches 85% (See Fig. 4 ). Recent-infection dominant and reactivation dominant describe scenarios where ratio of transmission and reactivation rate are altered from the baseline such that 5% and 80% of the active cases occur via reactivation, respectively (See Fig. 6 ). In these latter two scenarios, the parameter values commensurate to incidence levels of 75 and 300 per 100,000 per year are di↵erent and separately calculated; note that the reactivation rate cannot be taken down su ciently low to result in an incidence of 75 per 100,000 per year without concomitant reductions in one of the other parameters above (tabulated as NA).
Additional Results
Relationship between emergence of drug resistance and pre-existing resistance levels
Here we consider a scenario where there is pre-existing drug resistance, when a new drug regimen is introduced. In a population with pre-existing drug resistance at 2% (similar to current prevalence of fluoroquinolone monoresistance), the level of resistance at 5 years were modestly higher compared to settings in which there was no pre-existing DR-TB ( To simulate pre-existing resistance of 2%, we advance the model with no pre-existing resistance until the proportion of DR-TB reaches 2%, and then project 5 and 50 year trajectories from this time point. We compare the baseline scenario with an alternative scenario (Scenario III from Fig. 3) where the treatment success probability for DR-TB is reduced by an absolute 20%. Panels B and C show projections under the baseline and scenario III assumptions for populations without (B) and with (C) pre-existing resistance. Although the 5-year trajectories have minor di↵erences, the 50-year trajectories are nearly identical, regardless of whether resistance is pre-existing or not. Figure S-2: Trends in partial rank correlation coe cients (PRCC) between parameters and DR-TB proportion over time. Plotted are the partial rank correlation coe cients with DR-TB proportion at each of the first 50 years after the introduction of a new drug regimen, for each of the parameters indicated on the left column. The complete description of the parameter corresponding to the symbol can be found on Table 1 . Numerical values indicated on the graphs represent PRCC at years 5 and 50. The shaded grey region indicates the parameter values which lead to an e↵ective reproductive ratio of greater than 1. Three alternative scenarios are marked in purple: doubling the probability of de novo drug acquisition (Scenario I); increasing the transmission fitness of DR-TB by a relative 25% (Scenario II); and lowering the treatment success for DR-TB by an absolute 20% (Scenario III). As with proportion of DR-TB (in Fig. 3) , Scenario I has a modest e↵ect on both 5-year and 50-year projections, whereas Scenarios II and III (representing much smaller relative changes in corresponding parameter values) have little impact on 5-year projections but tremendous impact on the emergence of DR-TB at 50 years. ) after the introduction of a new first-line TB drug regimen. This figure is corresponds to Fig. 3 , but in the setting where the treatment success probability for DR-TB is 85% (equivalent to decreasing k to 0.1), representing a scenario in which DR-TB is rapidly detected with drug susceptibility testing, and then e↵ectively treated with second-line drugs. As in Fig. 3 , changes from the baseline condition (dashed vertical red line) are achieved by sequentially varying [A] the probability of acquiring de novo resistance during treatment, ✏; and [B] the relative transmission fitness, f , of DR-TB (vs DS-TB). The shaded grey region indicates the parameter values which lead to an e↵ective reproductive ratio of greater than 1. Two alternative scenarios are marked in purple. doubling the probability of de novo drug acquisition (Scenario I); and increasing the transmission fitness of DR-TB by a relative 25% (Scenario II). As with proportion of DR-TB (in Fig. 3 ), both scenarios result in low levels of DR-TB emergence even after 50 years, under the assumption of high DR-TB treatment success.
